Mechanism of action of colchicine in the treatment of gout

Clinical Therapeutics

Volumn 36, Issue 10, 2014, Pages 1465-1479

  Dalbeth, Nicola ^a   Lauterio, Thomas J ^b   Wolfe, Henry R ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b URL Pharma Inc   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

colchicine; gout; inflammatory arthritis; mechanism ofaction

Indexed keywords

COLCHICINE; COMPLEMENT; CRYOPYRIN; INFLAMMASOME; TUBULIN; TUMOR NECROSIS FACTOR ALPHA; URATE; ANTIGOUT AGENT; ANTIINFLAMMATORY AGENT;

ADVERSE DRUG REACTION; ARTICLE; CARDIOVASCULAR RISK; CELL INTERACTION; CELL SURFACE; CRYSTAL; DENDRITIC CELL; DRUG MECHANISM; DRUG SAFETY; DRUG USE; ENDOTHELIUM CELL; GENE DISRUPTION; GOUT; HUMAN; MACROPHAGE; MAST CELL; MICROTUBULE ASSEMBLY; MOLECULAR PATHOLOGY; MONOCYTE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NOCICEPTION; PHAGOCYTOSIS; PROTEIN EXPRESSION; RISK REDUCTION; TREATMENT OUTCOME; ANIMAL; CHRONIC DISEASE; IMMUNOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS;

EID: 84908284549     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.07.017     Document Type: Review

References (135)

1. W.N. Roberts, M.H. Liang, and S.H. Stern Colchicine in acute gout. Reassessment of risks and benefits JAMA 257 1987 1920 1922
2. M.J. Ahern, C. Reid, and T.P. Gordon Does colchicine work? The results of the first controlled study in acute gout Aust N Z J Med 17 1987 301 304
3. G.C. Borstad, L.R. Bryant, and M.P. Abel Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis J Rheumatol 31 2004 2429 2432
4. R.A. Terkeltaub, D.E. Furst, and K. Bennett High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study Arthritis Rheum 62 2010 1060 1068
5. D. Khanna, P.P. Khanna, and J.D. Fitzgerald 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis Arthritis Care Res (Hoboken) 64 2012 1447 1461
6. M. Hamburger, H.S. Baraf, T.C. Adamson, III 2011 Recommendations for the diagnosis and management of gout and hyperuricemia Postgrad Med 123 2011 3 36
7. C.A. Agudelo, and H.R. Schumacher The synovitis of acute gouty arthritis. A light and electron microscopic study Hum Pathol 4 1973 265 279
8. G. Ng, K. Sharma, and S.M. Ward Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells Immunity 29 2008 807 818
9. R.W. Fiddis, N. Vlachos, and P.D. Calvert Studies of urate crystallisation in relation to gout Ann Rheum Dis 42 Suppl 1 1983 12 15
10. H. Iwata, S. Nishio, and M. Yokoyama Solubility of uric acid and supersaturation of monosodium urate: why is uric acid so highly soluble in urine? J Urol 142 1989 1095 1098
11. I. Kippen, J.R. Klinenberg, A. Weinberger, and W.R. Wilcox Factors affecting urate solubility in vitro Ann Rheum Dis 33 1974 313 317
12. J.N. Loeb The influence of temperature on the solubility of monosodium urate Arthritis Rheum 15 1972 189 192
13. W.R. Wilcox, A. Khalaf, and A. Weinberger Solubility of uric acid and monosodium urate Med Biol Eng 10 1972 522 531
14. D. Perl-Treves, and L. Addadi A structural approach to pathological crystallizations. Gout: the possible role of albumin in sodium urate crystallization Proc R Soc Lond B Biol Sci 235 1988 145 159
15. M. Kam, D. Perl-Treves, D. Caspi, and L. Addadi Antibodies against crystals FASEB J 6 1992 2608 2613
16. M. Kam, D. Perl-Treves, R. Sfez, and L. Addadi Specificity in the recognition of crystals by antibodies J Mol Recognit 7 1994 257 264
17. U. Kanevets, K. Sharma, K. Dresser, and Y. Shi A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity J Immunol 182 2009 1912 1918
18. P.A. Guerne, R. Terkeltaub, B. Zuraw, and M. Lotz Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes Arthritis Rheum 32 1989 1443 1452
19. R.C. Landis, D.R. Yagnik, and O. Florey Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages Arthritis Rheum 46 2002 3026 3033
20. W.J. Martin, M. Walton, and J. Harper Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout Arthritis Rheum 60 2009 281 289
21. C. Schiltz, F. Liote, and F. Prudhommeaux Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events Arthritis Rheum 46 2002 1643 1650
22. F.S. Di Giovine, S.E. Malawista, G. Nuki, and G.W. Duff Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1 J Immunol 138 1987 3213 3218
23. Y. Shi, J.E. Evans, and K.L. Rock Molecular identification of a danger signal that alerts the immune system to dying cells Nature 425 2003 516 521
24. J. Tschopp, F. Martinon, and K. Burns NALPs: a novel protein family involved in inflammation Nat Rev Mol Cell Biol 4 2003 95 104
25. S. Mariathasan, K. Newton, and D.M. Monack Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf Nature 430 2004 213 218
26. F. Martinon, V. Petrilli, and A. Mayor Gout-associated uric acid crystals activate the NALP3 inflammasome Nature 440 2006 237 241
27. C. Dostert, V. Petrilli, and B.R. Van Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica Science 320 2008 674 677
28. V. Hornung, F. Bauernfeind, and A. Halle Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization Nat Immunol 9 2008 847 856
29. C. Jin, and R.A. Flavell Molecular mechanism of NLRP3 inflammasome activation J Clin Immunol 30 2010 628 631
30. V. Petrilli, S. Papin, and C. Dostert Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration Cell Death Differ 14 2007 1583 1589
31. R. Zhou, A. Tardivel, and B. Thorens Thioredoxin-interacting protein links oxidative stress to inflammasome activation Nat Immunol 11 2010 136 140
32. N.A. Thornberry, H.G. Bull, and J.R. Calaycay A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes Nature 356 1992 768 774
33. M. Yamamoto, K. Yaginuma, and H. Tsutsui ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adaptor molecules Genes Cells 9 2004 1055 1067
34. T. Misawa, M. Takahama, and T. Kozaki Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome Nat Immunol 14 2013 454 460
35. W.J. Martin, O. Shaw, and X. Liu Monosodium urate monohydrate crystal-recruited noninflammatory monocytes differentiate into M1-like proinflammatory macrophages in a peritoneal murine model of gout Arthritis Rheum 63 2011 1322 1332
36. N. Busso, and A. So Microcrystals as DAMPs and their role in joint inflammation Rheumatology (Oxford) 51 2012 1154 1160
37. R. Liu-Bryan, P. Scott, and A. Sydlaske Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation Arthritis Rheum 52 2005 2936 2946
38. F.S. Di Giovine, S.E. Malawista, E. Thornton, and G.W. Duff Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution J Clin Invest 87 1991 1375 1381
39. M. Pouliot, M.J. James, and S.R. McColl Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes Blood 91 1998 1769 1776
40. R. Terkeltaub, C. Zachariae, and D. Santoro Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation Arthritis Rheum 34 1991 894 903
41. F.A. Amaral, V.V. Costa, and L.D. Tavares NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout Arthritis Rheum 64 2012 474 484
42. M. Gaudry, C.J. Roberge, M.R. de, and A. Lussier Crystal-induced neutrophil activation. III. Inflammatory microcrystals induce a distinct pattern of tyrosine phosphorylation in human neutrophils J Clin Invest 91 1993 1649 1655
43. C.J. Roberge, M. Gaudry, and C. Gilbert Paradoxical effects of colchicine on the activation of human neutrophils by chemotactic factors and inflammatory microcrystal J Leukoc Biol 59 1996 864 871
44. I. Mitroulis, K. Kambas, and A. Chrysanthopoulou Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related signaling in gout PLoS One 6 2011 e29318
45. C. Schorn, C. Janko, and V. Krenn Bonding the foe - NETting neutrophils immobilize the pro-inflammatory monosodium urate crystals Front Immunol 3 2012 376
46. S.J. Getting, R.J. Flower, and L. Parente Molecular determinants of monosodium urate crystal-induced murine peritonitis: a role for endogenous mast cells and a distinct requirement for endothelial-derived selectins J Pharmacol Exp Ther 283 1997 123 130
47. H. Meng, M.G. Tonnesen, and M.J. Marchese Mast cells are potent regulators of endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression J Cell Physiol 165 1995 40 53
48. T.R. Fields, S.B. Abramson, and G. Weissmann Activation of the alternative pathway of complement by monosodium urate crystals Clin Immunol Immunopathol 26 1983 249 257
49. I.J. Russell, C. Papaioannou, and F.C. McDuffie Effect of IgG and C-reactive protein on complement depletion by monosodium urate crystals J Rheumatol 10 1983 425 433
50. P.C. Giclas, M.H. Ginsberg, and N.R. Cooper Immunoglobulin G independent activation of the classical complement pathway by monosodium urate crystals J Clin Invest 63 1979 759 764
51. I.J. Russell, C. Mansen, L.M. Kolb, and W.P. Kolb Activation of the fifth component of human complement (C5) induced by monosodium urate crystals: C5 convertase assembly on the crystal surface Clin Immunol Immunopathol 24 1982 239 250
52. N. Tramontini, C. Huber, and R. Liu-Bryan Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis Arthritis Rheum 50 2004 2633 2639
53. T.M. Cunha, W.A. Verri Jr., and I.R. Schivo Crucial role of neutrophils in the development of mechanical inflammatory hypernociception J Leukoc Biol 83 2008 824 832
54. T.M. Cunha, J. Talbot, and L.G. Pinto Caspase-1 is involved in the genesis of inflammatory hypernociception by contributing to peripheral IL-1beta maturation Mol Pain 6 2010 63
55. R. Terkeltaub, L.K. Curtiss, A.J. Tenner, and M.H. Ginsberg Lipoproteins containing apolipoprotein B are a major regulator of neutrophil responses to monosodium urate crystals J Clin Invest 73 1984 1719 1730
56. R.A. Terkeltaub, C.A. Dyer, J. Martin, and L.K. Curtiss Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo J Clin Invest 87 1991 20 26
57. E. Pascual, and V. Jovani A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout Br J Rheumatol 34 1995 724 726
58. T.D. Kennedy, C.S. Higgens, D.F. Woodrow, and J.T. Scott Crystal deposition in the knee and great toe joints of asymptomatic gout patients J R Soc Med 77 1984 747 750
59. A. Weinberger, H.R. Schumacher, and C.A. Agudelo Urate crystals in asymptomatic metatarsophalangeal joints Ann Intern Med 91 1979 56 57
60. N.J. Zvaifler, and T.J. Pekin Significance of urate crystals in synovial fluids Arch Intern Med 111 1963 99 102
61. T. Akahoshi, R. Namai, and Y. Murakami Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals Arthritis Rheum 48 2003 231 239
62. C. Jiang, A.T. Ting, and B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
63. M. Ricote, A.C. Li, and T.M. Willson The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
64. F. Liote, F. Prudhommeaux, and C. Schiltz Inhibition and prevention of monosodium urate monohydrate crystal-induced acute inflammation in vivo by transforming growth factor beta1 Arthritis Rheum 39 1996 1192 1198
65. V.A. Fadok, D.L. Bratton, and A. Konowal Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF J Clin Invest 101 1998 890 898
66. S. Steiger, and J.L. Harper Neutrophil cannibalism triggers transforming growth factor beta1 production and self regulation of neutrophil inflammatory function in monosodium urate monohydrate crystal-induced inflammation in mice Arthritis Rheum 65 2013 815 823
67. D.R. Yagnik, B.J. Evans, and O. Florey Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation Arthritis Rheum 50 2004 2273 2280
68. A. Scanu, F. Oliviero, and R. Ramonda Cytokine levels in human synovial fluid during the different stages of acute gout: role of transforming growth factor beta1 in the resolution phase Ann Rheum Dis 71 2012 621 624
69. Y.H. Chen, S.C. Hsieh, and W.Y. Chen Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFbeta1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3 Ann Rheum Dis 70 2011 1655 1663
70. R.W. Jackman, M.G. Rhoads, E. Cornwell, and S.C. Kandarian Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway Exp Cell Res 315 2009 3242 3249
71. A.H. Ding, F. Porteu, E. Sanchez, and C.F. Nathan Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents J Exp Med 171 1990 715 727
72. B.N. Cronstein, Y. Molad, and J. Reibman Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils J Clin Invest 96 1995 994 1002
73. E.W. Chia, R. Grainger, and J.L. Harper Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine Br J Pharmacol 153 2008 1288 1295
74. T. Oka, M. Hori, and H. Ozaki Microtubule disruption suppresses allergic response through the inhibition of calcium influx in the mast cell degranulation pathway J Immunol 174 2005 4584 4589
75. H. Sayarlioglu, E. Dogan, and R. Erkoc The effect of colchicine on the peritoneal membrane Ren Fail 28 2006 69 75
76. T.W. Kuijpers, M. Raleigh, and T. Kavanagh Cytokine-activated endothelial cells internalize E-selectin into a lysosomal compartment of vesiculotubular shape. A tubulin-driven process J Immunol 152 1994 5060 5069
77. S. Paschke, A.F. Weidner, and T. Paust Technical advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments J Leukoc Biol 94 2013 1091 1096
78. O. Chappey, E. Niel, and M. Dervichian Colchicine concentration in leukocytes of patients with familial Mediterranean fever Br J Clin Pharmacol 38 1994 87 89
79. P. Sherline, J.T. Leung, and D.M. Kipnis Binding of colchicine to purified microtubule protein J Biol Chem 250 1975 5481 5486
80. J.M. Andreu, and S.N. Timasheff Tubulin bound to colchicine forms polymers different from microtubules Proc Natl Acad Sci U S A 79 1982 6753 6756
81. R.F. Luduena, and M.C. Roach Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents Pharmacol Ther 49 1991 133 152
82. J.P. Caviston, and E.L. Holzbaur Microtubule motors at the intersection of trafficking and transport Trends Cell Biol 16 2006 530 537
83. C.J. Roberge, M. Gaudry, M.R. de, and A. Lussier Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine J Clin Invest 92 1993 1722 1729
84. H. Asako, P. Kubes, and B.A. Baethge Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venules Inflammation 16 1992 45 56
85. O.A. Dina, G.C. McCarter, C.C. de, and J.D. Levine Role of the sensory neuron cytoskeleton in second messenger signaling for inflammatory pain Neuron 39 2003 613 624
86. L. Ning, C. Wang, and X. Fan Role of colchicine-induced microtubule depolymerization in hyperalgesia via TRPV in rats with chronic compression of the dorsal root ganglion Neurol Res 36 2014 70 78
87. R. Schuligoi Effect of colchicine on nerve growth factor-induced leukocyte accumulation and thermal hyperalgesia in the rat Naunyn Schmiedebergs Arch Pharmacol 358 1998 264 269
88. N. Dalbeth, and T. Merriman Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout Rheumatology (Oxford) 48 2009 222 226
89. S. Lim, E. Bae, and H.S. Kim TRAF6 mediates IL-1beta/LPS-induced suppression of TGF-beta signaling through its interaction with the type III TGF-beta receptor PLoS One 7 2012 e32705
90. M. Sahin, A. Cihangir Uguz, H. Demirkan, and M. Nazirolglu Colchicine Modulates Oxidative Stress in Serum and Leucocytes from Remission Patients with Family Mediterranean Fever Through Regulation of Ca2+ Release and the Antioxidant System J Membr Biol 240 2011 55 62
91. E.Z. Taskiran, A. Cetinkaya, and B. Balci-Peynircioglu The effect of colchicine on pyrin and pyrin interacting proteins J Cell Biochem 113 2012 3536 3546
92. R.A. Bonnel, M.L. Villalba, C.B. Karwoski, and J. Beitz Deaths associated with inappropriate intravenous colchicine administration J Emerg Med 22 2002 385 387
93. Colcrys [package insert] 2009 Mutual Pharmaceutical Company Philadelphia, PA
94. G.M. Ferron, M. Rochdi, W.J. Jusko, and J.M. Scherrmann Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses J Clin Pharmacol 36 1996 874 883
95. T. Tateishi, P. Soucek, and Y. Caraco Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation Biochem Pharmacol 53 1997 111 116
96. A. Dahan, H. Sabit, and G.L. Amidon Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine Drug Metab Dispos 37 2009 2028 2036
97. R. Harris, G. Marx, and M. Gillett Colchicine-induced bone marrow suppression: treatment with granulocyte colony-stimulating factor J Emerg Med 18 2000 435 440
98. M.A. Tanios, G.H. El, S.K. Epstein, and P.M. Hassoun Severe respiratory muscle weakness related to long-term colchicine therapy Respir Care 49 2004 189 191
99. R.W. Kuncl, G. Duncan, and D. Watson Colchicine myopathy and neuropathy N Engl J Med 316 1987 1562 1568
100. R.A. Terkeltaub, D.E. Furst, and J.L. Digiacinto Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors Arthritis Rheum 63 2011 2226 2237
101. US Food and Drug Administration. Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174315.htm. Accessed June 5, 2014.
102. G. Alayli, K. Cengiz, and F. Canturk Acute myopathy in a patient with concomitant use of pravastatin and colchicine Ann Pharmacother 39 2005 1358 1361
103. E.M. Atasoyu, T.R. Evrenkaya, and E. Solmazgul Possible colchicine rhabdomyolysis in a fluvastatin-treated patient Ann Pharmacother 39 2005 1368 1369
104. M. Justiniano, S. Dold, and L.R. Espinoza Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine J Clin Rheumatol 13 2007 266 268
105. I. Chattopadhyay, H.G. Shetty, P.A. Routledge, and J. Jeffery Colchicine induced rhabdomyolysis Postgrad Med J 77 2001 191 192
106. Y. Finkelstein, S.E. Aks, and J.R. Hutson Colchicine poisoning: the dark side of an ancient drug Clin Toxicol (Phila) 48 2010 407 414
107. M.E. Mullins, E.A. Carrico, and B.Z. Horowitz Fatal cardiovascular collapse following acute colchicine ingestion J Toxicol Clin Toxicol 38 2000 51 54
108. P. Mery, B. Riou, D. Chemla, and Y. Lecarpentier Cardiotoxicity of colchicine in the rat Intensive Care Med 20 1994 119 123
109. S. Aran, S. Malekzadeh, and S. Seifirad A double-blind randomized controlled trial appraising the symptom-modifying effects of colchicine on osteoarthritis of the knee Clin Exp Rheumatol 29 2011 513 518
110. M. Attur, I. Belitskaya-Levy, and C. Oh Increased interleukin-1beta gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis Arthritis Rheum 63 2011 1908 1917
111. N.A. Bracey, P.L. Beck, and D.A. Muruve The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta Exp Physiol 98 2013 462 472
112. S.K. Das, S. Ramakrishnan, and K. Mishra A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report Arthritis Rheum 47 2002 280 284
113. E. Roddy, and M. Doherty Gout and osteoarthritis: A pathogenetic link? Joint Bone Spine 79 2012 425 427
114. C. Melchiorri, R. Meliconi, and L. Frizziero Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis Arthritis Rheum 41 1998 2165 2174
115. L.C. Tetlow, D.J. Adlam, and D.E. Woolley Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes Arthritis Rheum 44 2001 585 594
116. J.C. Fernandes, J. Martel-Pelletier, and J.P. Pelletier The role of cytokines in osteoarthritis pathophysiology Biorheology 39 2002 237 246
117. K.W. Finnson, Y. Chi, and G. Bou-Gharios TGF-b signaling in cartilage homeostasis and osteoarthritis Schol Front Biosci 4 2012 251 268
118. J.A. Roman-Blas, D.G. Stokes, and S.A. Jimenez Modulation of TGF-beta signaling by proinflammatory cytokines in articular chondrocytes Osteoarthritis Cartilage 15 2007 1367 1377
119. J.W. Rachow, and L.M. Ryan Adenosine triphosphate pyrophosphohydrolase and neutral inorganic pyrophosphatase in pathologic joint fluids. Elevated pyrophosphohydrolase in calcium pyrophosphate dihydrate crystal deposition disease Arthritis Rheum 28 1985 1283 1288
120. P.R. Hearn, and R.G. Russell Formation of calcium pyrophosphate crystals in vitro: implications for calcium pyrophosphate crystal deposition disease (pseudogout) Ann Rheum Dis 39 1980 222 227
121. R.M. Bennett, J.R. Lehr, and D.J. McCarty Factors affecting the solubility of calcium pyrophosphate dihydrate crystals J Clin Invest 56 1975 1571 1579
122. N. Busso, and A. So Mechanisms of inflammation in gout Arthritis Res Ther 12 2010 206
123. W. Zhang, M. Doherty, and E. Pascual EULAR recommendations for calcium pyrophosphate deposition. Part II: management Ann Rheum Dis 70 2011 571 575
124. V. Gagne, L. Marois, and J.M. Levesque Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications Arthritis Res Ther 15 2013 R73
125. L. Pang, C.P. Hayes, and K. Buac Pseudogout-associated inflammatory calcium pyrophosphate dihydrate microcrystals induce formation of neutrophil extracellular traps J Immunol 190 2013 6488 6500
126. R.J. McKendry, G. Kraag, S. Seigel, and A. al-Awadhi Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis Ann Rheum Dis 52 1993 826 828
127. J. Zuckner Responses to Colchicine Therapeutic Trial in Rheumatoid Arthritis New England Journal of Medicine 267 1962 682 686
128. R.T. Keenan, W.R. O'Brien, and K.H. Lee Prevalence of contraindications and prescription of pharmacologic therapies for gout Am J Med 124 2011 155 163
129. H.K. Choi, and G. Curhan Independent impact of gout on mortality and risk for coronary heart disease Circulation 116 2007 894 900
130. E. Krishnan, J.F. Baker, D.E. Furst, and H.R. Schumacher Gout and the risk of acute myocardial infarction Arthritis Rheum 54 2006 2688 2696
131. M. Nidorf, and P.L. Thompson Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease Am J Cardiol 99 2007 805 807
132. N.C. Raju, Q. Yi, and M. Nidorf Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial J Thromb Thrombolysis 33 2011 88 94
133. J.L. Martin-Ventura, J. Madrigal-Matute, and R. Martinez-Pinna Erythrocytes, leukocytes and platelets as a source of oxidative stress in chronic vascular diseases: detoxifying mechanisms and potential therapeutic options Thromb Haemost 108 2012 435 442
134. D.B. Crittenden, R.A. Lehmann, and L. Schneck Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout J Rheumatol 39 2012 1458 1464
135. S.M. Nidorf, J.W. Eikelboom, C.A. Budgeon, and P.L. Thompson Low-dose colchicine for secondary prevention of cardiovascular disease J Am Coll Cardiol 61 2013 404 410